The antiangiogenic and antitumoral activity of titanocene Y* in Vivo

Letters in Drug Design and Discovery

Volumn 8, Issue 4, 2011, Pages 302-307

  Fichtner, Iduna ^a   Behrens, Diana ^b   Claffey, James ^c   Deally, Anthony ^c   Gleeson, Brendan ^c   Patil, Siddappa ^c   Weber, Holger ^d   Tacke, Matthias ^c  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b Experimental Pharmacology and Oncology EPO GmbH   (Germany)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d PROQINASE GMBH   (Germany)

Author keywords

Anti angiogenic drug; Anticancer drug; HUVEC; Renal cell cancer; Titanocene; Xenograft

Indexed keywords

KI 67 ANTIGEN; TITANOCENE DICHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOLOGY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

EID: 79955953924     PISSN: 15701808     EISSN: 1875628X     Source Type: Journal    
DOI: 10.2174/157018011794839367     Document Type: Article

References (22)

1. Surveillance Epidemiology and End Results. National Cancer Institute; 2007. Available from: www.seer.cancer.gov
2. Schrader, A.J.; Hofmann, R. Metastatic renal cell carcinoma: recent advances and current therapeutic options. Anti-Cancer Drugs, 2008, 19, 235-245.
3. Lummen, G.; Sperling, H.; Luboldt, H.; Otto, T.; Rubben, H. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemother. Pharmacol., 1998, 42, 415-417. (Pubitemid 28430373)
4. Kröger, N.; Kleeberg, U.R.; Mross, K.B.; Edler, L.; Saß, G.; Hossfeld, D.K. Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer. Onkologie, 2000, 23, 60-62. (Pubitemid 30154851)
5. Allen, O.R.; Croll, L.; Gott, A.L.; Knox, R.J.; McGowan, P.C. Functionalized cyclopentadienyl titanium organometallic compounds as new antitumor drugs. Organometallics, 2004, 23, 288-292.
6. Strohfeldt, K.; Tacke, M. Bioorganometallic fulvene-derived titanocene anticancer drugs. Chem. Soc. Rev., 2008, 37, 1174-1187.
7. Sweeney, N.J.; Mendoza, O.; Müller-Bunz, H.; Pampillön, C.; Rehmann, F.J.K.; Strohfeldt, K.; Tacke, M. Novel benzyl substituted titanocene anti-cancer drugs. J. Organomet. Chem., 2005, 690, 4537-4544. (Pubitemid 41436516)
8. Kelter, G.; Sweeney, N.; Strohfeldt, K.; Fiebig, H.H.; Tacke, M. In vitro Anti-tumor activity of bridged and unbridged benzylsubstituted titanocenes. Anti-Cancer Drugs, 2005, 16, 1091-1098. (Pubitemid 41568594)
9. Oberschmidt, O.; Hanauske, A.R.; Rehmann, F.J.K.; Strohfeldt, K.; Sweeney, N.; Tacke, M. Activity of [1,2-di(cyclopentadienyl)-1,2- di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride against tumor colony forming units. Anti-Cancer Drugs, 2005, 16, 1071-1073. (Pubitemid 41565772)
10. Oberschmidt, O.; Hanauske, A.R.; Pampillón, C.; Sweeney, N.J.; Strohfeldt, K.; Tacke, M. Activity of titanocene Y against tumor colony forming units. Anti-Cancer Drugs, 2007, 18, 317-321. (Pubitemid 46192986)
11. O'Connor, K.; Gill, C.; Tacke, M.; Rehmann, F.J.K.; Strohfeldt, K.; Sweeney, N.; Fitzpatrick, J.M.; Watson, R.W.G. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells. Apoptosis, 2006, 11, 1205-1214. (Pubitemid 44035968)
12. Valadares, M.C.; Ramos, A.L.; Rehmann, F.J.K.; Sweeney, N.J.; Strohfeldt, K.; Tacke, M.; Queiroz, M.L.S. Antitumor activity of [1,2-di(cyclopentadienyl)- 1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumor. Eur. J. Pharmacol., 2006, 534, 264-270.
13. Weber, H.; Claffey, J.; Hogan, M.; Pampillón, C.; Tacke, M. Analyses of titanocenes in the spheroid-based cellular angiogenesis assay. Toxicol. In Vitro, 2008, 22, 531-534. (Pubitemid 351163538)
14. Fichtner, I.; Bannon, J.; O'Neill, A.; Pampillón, C.; Sweeney, N.J.; Strohfeldt, K.; Watson, R.W.G.; Tacke, M.; McGee, M.M. Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit anti-tumour activity in vivo. Br. J. Cancer, 2007, 97, 1234-1241. (Pubitemid 350035811)
15. Dowling, C.M.; Claffey, J.; Cuffe, S.; Fichtner, I.; Pampillón, C.; Sweeney, N.J.; Strohfeldt, K.; Watson, R.W.G.; Tacke, M. Antitumor activity of titanocene y in xenografted PC3 tumors in mice. Lett. Drug Des. Discov., 2008, 5, 141-144. (Pubitemid 351481958)
16. Fichtner, I.; Pampillón, C.; Sweeney, N.J.; Strohfeldt, K.; Tacke, M. Antitumor activity of titanocene Y in xenografted caki-1 tumors in mice. Anti-Cancer Drugs, 2006, 17, 333-336.
17. Beckhove, P.; Oberschmidt, O.; Hanauske, A.R.; Pampillón, C.; Schirrmacher, V.; Sweeney, N.J.; Strohfeldt, K.; Tacke, M. Antitumor activity of titanocene Y in freshly explanted human breast tumors and in xenografted MCF-7 tumors in mice. Anti-Cancer Drugs, 2007, 18, 311-315. (Pubitemid 46192985)
18. Fichtner, I.; Behrens, D.; Claffey, J.; Deally, A.; Gleeson, B.; Hogan, M.; Weber, H.; Tacke, M. Antitumor activity of vanadocene Y and its selenocyanate derivative in xenografted CAKI-1 tumors in mice. J. Organometal. Chem., 2010, 695, 1175-1181.
19. Claffey, J.; Hogan, M.; Müller-Bunz, H.; Pampillón, C.; Tacke, M. Oxali-Titanocene Y: A Potent Anticancer Drug. ChemMedChem, 2008, 3, 729-731.
20. Claffey, J.; Müller-Bunz, H.; Tacke, M. Benzyl-substituted titanocene dichloride anticancer drugs: from lead to hit. J. Organometal. Chem., 2010, 695, 2105-2117.
21. Korff, T.; Augustin, H.G. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J. Cell. Biol., 1998, 143, 1341-1352. (Pubitemid 28559834)
22. Korff, T.; Augustin, H.G. Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J. Cell. Sci., 1999, 772, 3249-3258. (Pubitemid 29507205)